Objective
The aim of this study was to assess the feasibility of 18F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) to systematically detect and quantify differential effects of chronic tobacco use in organs of the whole body.
Methods
20 healthy male subjects (10 non-smokers and 10 chronic heavy smokers) were enrolled. Subjects underwent whole-body FDG-PET/CT, diagnostic unenhanced chest CT, mini-mental state examination (MMSE), urine testing for oxidative stress and serum testing.
Organs of interest (thyroid, skin, skeletal muscle, aorta, heart, lung, adipose tissue, liver, spleen, brain, lumbar spinal bone marrow, and testis) were analyzed from FDG-PET/CT images to determine their metabolic activities using standardized uptake value (SUV) or metabolic volumetric product (MVP). Measurements were compared between subject groups using 2-sample t-tests or Wilcoxon rank-sum tests as determined by tests for normality. Correlational analyses were also performed.
Results
FDG-PET/CT revealed significantly decreased metabolic activity of lumbar spinal bone marrow (MVPmean 29.8±9.7 cc vs. 40.8±11.6 cc, p=0.03) and liver (SUVmean 1.8±0.2 vs. 2.0±0.2, p=0.049), and increased metabolic activity of visceral adipose tissue (VAT) (SUVmean 0.35±0.10 vs. 0.26±0.06, p=0.02) in chronic smokers compared to non-smokers. Normalized VAT volume was also significantly decreased (p=0.04) in chronic smokers. There were no statistically significant differences in the metabolic activity of other assessed organs.
Conclusions
Subclinical organ effects of chronic tobacco use are detectable and quantifiable on FDG-PET/CT. FDG-PET/CT may therefore play a major role in the study of systemic toxic effects of tobacco use in organs of the whole body for clinical or research purposes.